Quick answer: Evidence in the peptide category runs from cell cultures through animal work to small human studies and, rarely, randomized controlled trials. Strength increases as you move up that ladder, and most claims circulating about peptides rest on the bottom two rungs, where results in a dish or a rodent frequently fail to reproduce in people. Reading a claim well means asking what type of study produced it, how many participants, for how long, measuring what, and funded by whom. The phrase "studies show" means nothing until you can name the study.
Evidence literacy is the difference between accepting a conclusion and evaluating one. Nobody needs a research degree to do this; the questions are few and the databases are public. What follows is the method, then how it applies to a category where preclinical work is often presented as though it settled something.
The hierarchy, from cells to systematic reviews
Study designs form a ladder, and where a finding sits determines how much weight it carries. In vitro work exposes cells or tissue in a dish to a compound and shows what can happen under controlled artificial conditions. Animal studies add a whole organism, usually a rodent, with a metabolism and lifespan very different from yours.
Human research begins above that. Small open-label studies give a therapy to a handful of people who know they are receiving it, with no comparison group, which makes them useful for spotting safety signals and nearly useless for proving effect. Randomized controlled trials assign participants to treatment or control by chance and, when blinded, prevent expectation from shaping either the reporting or the assessment.
Systematic reviews and meta-analyses sit at the top by pooling every qualifying trial under a stated method. Quality still depends on the inputs, since pooling weak trials produces a well-organized weak conclusion.
Why animal results so often fail in people
Animal work earns its place and also has a well-documented failure rate on the way to human use. Rodents differ from humans in metabolism, receptor distribution, immune function and lifespan, and laboratory animals are typically genetically uniform, young, healthy and housed in controlled conditions that no patient population resembles. Doses used in animal studies are also frequently far higher relative to body weight than anything given to a person.
Publication practices widen the gap. Positive animal findings are published far more readily than null ones, so the visible literature is skewed before anyone tries to replicate it, and much of the tissue-repair and recovery research circulating in the peptide space is exactly this kind of preclinical work. Treat a rodent result as a reason for a human trial rather than as a preview of one.
Sample size, duration and who dropped out
Sample size determines whether a result is signal or noise. Twelve participants can produce a striking average that a single unusual responder created, which is why small studies swing wildly and larger ones move less. Look for the number of participants before you look at the effect, and check how many dropped out, since the people who finish may be the ones who tolerated the therapy best.
Duration decides which questions the study could answer. An eight-week study cannot describe what happens over a year, and safety questions that matter most for a therapy someone might use for years are the ones short trials are structurally unable to address. Sustained effect and long-term tolerability are separate claims requiring separate evidence.
Surrogate markers versus outcomes that matter
Surrogate markers are laboratory values that stand in for the thing you actually care about. A study can show that a compound raises a circulating hormone or shifts a blood marker without ever showing that anyone slept better, recovered faster or lived longer, and the marker is easier and cheaper to measure. Marker movement is a mechanism finding.
Medical history holds several cautionary examples where a marker improved and the clinical outcome did not follow, or worsened. Ask what the study measured, then ask whether that measurement is the outcome you want or a proxy for it, and treat the gap between the two as real rather than as a formality. Our explanation of how sermorelin works through the pituitary and what the research does and does not show keeps that distinction explicit.
Funding, conflicts and preprints
Funding does not invalidate a study, and ignoring it is careless. Industry-funded research is more likely to report results favorable to the sponsor across many fields, so a disclosed commercial interest is a reason to read the methods more slowly rather than to dismiss the paper. Disclosure statements appear at the end of the paper.
Peer review is a filter, not a certification. Reviewers catch some errors and miss others, and plenty of peer-reviewed work is later contradicted, but the process removes a layer of obvious problems. Preprints, posted publicly before review, can be excellent and can also be entirely unvetted, so a preprint cited as settled science is being oversold.
How to find the study yourself
PubMed is free, maintained by the National Library of Medicine, and indexes most biomedical literature. Search the compound name plus a term for the question you have, then use the filters on the left to restrict results to clinical trial, randomized controlled trial, meta-analysis or systematic review, and to human studies rather than animal ones. Sorting by date shows you where the field currently stands.
Reading an abstract well takes about a minute. Note the species, the number of participants, the duration, the comparison group if there is one, and what was measured, then check whether the conclusion matches those parameters or reaches beyond them. ClinicalTrials.gov shows registered and ongoing trials, which is useful for seeing what is genuinely under investigation.
Applying the method to this category is clarifying. Much of what circulates about repair and recovery peptides is preclinical, while some prescribed therapies have decades of human data behind them. Start with a plain description of what peptides are and how they signal in the body, then check any specific claim yourself.
Frequently Asked Questions
What is the difference between in vitro, animal and human studies?
In vitro studies test cells or tissue outside a living body under artificial conditions. Animal studies use a whole organism, usually a rodent, whose physiology differs substantially from human physiology. Human studies range from small uncontrolled series to randomized controlled trials, and only the human tier can describe what a therapy does in people.
Why do animal studies often not translate to humans?
Animal studies use genetically uniform, young, healthy animals in controlled conditions, frequently at doses far higher relative to body weight than any human would receive. Differences in metabolism, receptor biology and lifespan all reduce transferability. Positive animal findings are also published more readily than null ones, which skews the visible literature.
How many participants make a study meaningful?
Sample size thresholds vary, because the number needed depends on the size of the effect and how variable it is. Very small studies of a dozen or so participants are exploratory and easily distorted by one unusual responder. Larger, longer, randomized studies with a control group carry more weight than any small one.
What is a surrogate marker?
A surrogate marker is a measurement used as a stand-in for an outcome that matters to a person, such as a blood value substituting for how someone actually feels or functions. Markers are cheaper and faster to measure, which is why studies use them. Marker improvement does not reliably predict clinical improvement.
How do I look up a study on PubMed?
Searching PubMed starts with the compound name and a term for your question, followed by the article-type filters for randomized controlled trial, meta-analysis or systematic review. Restrict to human studies to exclude animal work. Read the abstract for species, sample size, duration and what was measured before reading the conclusion.
The honest summary
Five questions cover most of what you need: what kind of study, how many people, for how long, measuring what, funded by whom. Applying them will lower your confidence in much of what is marketed in this category, which is the correct outcome, because a great deal of the peptide literature is preclinical and preclinical results routinely fail in humans.
Evidence answers one half of the decision, and the provider answers the other. Once you can judge a claim, run the license, pharmacy and testing checks that confirm who is actually behind a product, and learn the marketing patterns that signal a seller is overstating what the research supports. A prescribing clinician who knows your history applies both to you specifically.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID 41966639.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology. 2021. PMID 34267654.
Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of internal medicine. 2007. PMID 17227934.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.